cgp-56999a and Parkinsonian-Disorders

Rats were injected (i.p.) once daily with either 1 mg/kg CGP 56999A, a gamma-aminobutyric acid(B) (GABA(B)) receptor antagonist, or an equivalent volume of saline beginning 7 days prior to, and continuing for 7 days following, a unilateral 6-hydroxydopamine lesion of the nigrostriatal dopamine (DA) pathway. At the end of the CGP 56999A treatment period the concentrations of DA and dihydroxyphenylacetic acid (DOPAC), as well as the expression of brain-derived neurotrophic factor (BDNF), were analyzed in corpus striatum ipsilateral and contralateral to the lesioning. No significant differences in these parameters were noted in the contralateral striatum between saline- and CGP 56999A-treated subjects. In contrast, as compared to animals receiving saline only, daily treatment with the GABA(B) receptor antagonist significantly attenuated the 6-hydroxydopamine-induced decline in DA and increased the expression of BDNF in the ipsilateral striatum. The results indicate that CGP 56999A enhances BDNF gene expression in the rat corpus striatum and prevents the decline in DA content that is a characteristic sequela of 6-hydroxydopapmine lesions of the nigrostraital dopamine pathway. These findings suggest that GABA(B) receptor antagonists may be of value in the treatment of Parkinson's disease and other conditions that would benefit from an enhanced production of neurotrophic factors in brain.

Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; GABA Antagonists; GABA-B Receptor Antagonists; Gene Expression; Male; Neural Inhibition; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Phosphinic Acids; Rats; Rats, Inbred F344; Receptors, GABA-B; Substantia Nigra; Sympatholytics; Synaptic Transmission; Treatment Outcome; Up-Regulation